Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 29 of the 56 sources its claims cite were checked for support.

PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future

Open access
Ayzman, Ann, Pachynski, Russell K., Reimers, Melissa A. · 2025 · Current Treatment Options in Oncology

Abstract

OPINION STATEMENT: The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving with the advent of PSMA-targeted radioligand therapies (RLTs) and bispecific T-cell engagers (BiTEs). These novel approaches provide new hope for patients who have progressed on standard therapies. However, their full clinical potential will be realized only by addressing key challenges, including tumor heterogeneity, resistance mechanisms, immune-related toxicities, and the immunosuppressive tumor microenvironment. Additionally, the optimal sequencing of these therapies at different stages of disease remains an open question. While most of these interventions are currently introduced in late-stage, heavily pretreated patients, ongoing clinical trials are exploring their role in earlier disease settings, where they may be more effective in altering the natural history of disease. PSMA-based RLTs, such as 177Lu-PSMA- 617, have demonstrated promising efficacy, particularly in patients with high PSMA expression. However, the presence of PSMA-negative or heterogeneous tumors necessitates the development of additional biomarkers and combination strategies. The ongoing PSMAddition trial may establish RLTs as an earlier-line treatment in hormone-sensitive metastatic prostate cancer, potentially shifting the standard of care. Moreover, mitigating toxicities through radioprotective agents may aid in expanding their clinical utility. BiTE therapies offer a different but complementary mechanism of action, leveraging T-cell engagement to drive tumor cell destruction. While cytokine release syndrome (CRS) and immunogenicity remain significant hurdles, modifications such as low-affinity CD3 binding and optimized dosing regimens are showing promise. The potential synergy of BiTEs with immune checkpoint inhibitors and tumor microenvironment-modulating agents should be further explored to enhance therapeutic efficacy. Given these advancements, the future of mCRPC treatment likely lies in a personalized, multimodal approach that integrates PSMA-based RLTs, BiTEs, and complementary therapies at earlier disease stages. Strategic biomarker-driven patient selection and combination regimens will be essential in optimizing outcomes while minimizing resistance and toxicity.

Overview

CoChat Summary

## TL;DR

This review summarizes emerging PSMA-based therapies and bispecific T-cell engagers for advanced prostate cancer, emphasizing how radioligand therapy and BiTEs are reshaping treatment of mCRPC. It concludes that these approaches are promising but still limited by heterogeneity, resistance, immunogenicity, and toxicity, and that earlier-line and combination strategies are under active study.

## Key findings

  • In the phase III VISION trial, 177Lu-PSMA-617 improved overall survival (median 15.3 vs 11.3 months; HR 0.62, P < 0.001) and radiographic PFS (median 8.7 vs 3.4 months; HR 0.40, P < 0.001) versus standard care.
  • In PSMAfore, 177Lu-PSMA-617 improved rPFS in taxane-naïve mCRPC after ARPI progression (11.6 vs 5.59 months; HR 0.49), with lower grade 3–5 adverse events than control and OS not yet mature.
  • In the phase I acapatamab study, 133 patients had a 30.4% PSA50 response; CRS occurred in 97.4% during dose exploration and 98.2% during dose expansion, with grade ≥3 CRS in 23.4% and 16.1%, respectively; TE-ADAs were detected in 55% and affected exposure in 36%.
  • In the phase 1a ENGAGER-PSMA-01 study of JANX0007, 16 heavily pre-treated mCRPC patients had 100% PSA50, 63% PSA90, and 31% PSA99 responses; CRS events were mainly cycle 1 and grades 1–2.
  • For xaluritamig (AMG 509), a phase 1 study enrolled 97 heavily pretreated mCRPC patients and found 49% PSA50 and 30% PSA90 responses; CRS occurred in 72%, mostly during cycle 1, and 3% discontinued because of CRS.

## Methods

  • Narrative review of PSMA-based therapies and BiTE therapies in advanced prostate cancer, with emphasis on mCRPC and some earlier-stage settings.
  • Synthesizes data from phase 1, phase 2, phase 3, and retrospective studies, including trials such as VISION, PSMAfore, PSMAddition, ECLIPSE, SPLASH, and multiple BiTE/ADC studies.
  • The article mainly uses descriptive comparison of trial outcomes (e.g., OS, rPFS, PSA50/PSA90, CRS, TE-ADAs, response rates, safety signals) rather than a new primary analysis.

## Limitations

  • The paper itself states that tumor heterogeneity, PSMA-negative or heterogeneous tumors, primary and acquired resistance, immunogenicity, CRS, and the immunosuppressive tumor microenvironment limit efficacy and wider adoption.
  • It notes that optimal sequencing, best dosing strategies, and how to mitigate toxicities remain unresolved. It also states that some trial designs may be limited by bias favoring experimental arms, non-representative control arms, stringent inclusion criteria, and the requirement for PSMA-positivity, which may reduce generalizability.
  • Evident from the text: this is a review article, so it does not present a single unified patient cohort or original controlled analysis; instead, it compiles results across heterogeneous studies and endpoints.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11864-025-01317-5

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

29 Valid · 0 Not valid · 25 Not checked · 6 Own results and interpretations

24 more claims · 11 with their cited sources checked

Create a free account to see all 60 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 30
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Citations

Cites

Show all 42 references

Research works printed but not linked: 3

  1. Mutevelic S, Patterson M. Curium announces ECLIPSE trial has met primary endpoint, demonstrating a statistically significant and clinically meaningful benefit for patients with PSMA-positive metastatic castration resistant prostate cancer. Curium Pharma Press Release. 2024. https://www.curiumpharma.com/2024/11/13/eclipse-tiral-psma-prostate-cancer/.
  2. Hurley, S. LAVA reports third quarter 2024 financial results and announces pipeline reprioritization and cash runway extension into 2027. LAVA therapeutics press release. Dec 10 2024. https://ir.lavatherapeutics.com/news-releases/news-release-details/lava-reports-third-quarter-2024-financial-results-and-announces.
  3. Campbell, D. Janux announces doses selected for phase 1b expansion trials supported by encouraging efficacy and safety profile observed in phase 1a dose escalation for JANX007 in mCRPC. Janux therapeutics press release. Dec 2 2024. https://investors.januxrx.com/investor-media/news/news-details/2024/Janux-Announces-Doses-Selected-for-Phase-1b-Expansion-Trials-Supported-by-Encouraging-Efficacy-and-Safety-Profile-Observed-in-Phase-1a-Dose-Escalation-for-JANX007-in-mCRPC/default.aspx.

Cited by

See all 18

Metadata

Authors
Ayzman, A., Pachynski, R. K., & Reimers, M. A.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Reimers, Melissa A.
Venue
Current Treatment Options in Oncology
Published
2025-04-23
Volume
26
Issue
5
Pages
375-384
ISSN
  • 1527-2729 (ISSN-L)
  • 1534-6277
OpenAlex
W4409704743
Cited by
18
References
42
Citations by year
2026: 14 · 2025: 4
FWCI
3.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Treatment Options in Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
metastatic castration-resistant prostate cancer, PSMA radioligand therapy, 177Lu-PSMA-617, bispecific T-cell engagers, tumor heterogeneity, treatment resistance, immune-related toxicity, cytokine release syndrome, tumor microenvironment, immunosuppression, radiation protection, biomarkers, hormone-sensitive prostate cancer, immune checkpoint inhibitors, combination therapy
MeSH terms
Antigens, Surface, Combined Modality Therapy, Humans, Male, Neoplasm Staging, Prostatic Neoplasms, Biomarkers, Tumor, Treatment Outcome, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Molecular Targeted Therapy, Tumor Microenvironment, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future. https://app.cochat.ai/papers/10.1007/s11864-025-01317-5
The paper
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025). PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-025-01317-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.